Felicity Pharma is a biotech company focused on drug development for the treatment of mood disorders in women.
We are passionate about changing the paradigm when it comes to women and their medical needs and we put women first.
We create real solutions for women with mood disorders by disrupting antidepressant markets.
We are working with novel compounds to create solutions for various female-specific disorders.
We are using the leading molecular AI technology to reduce Drug Development timelines.
Female’s want and deserve products that are created to be gender specific.
We bring new solutions, creative thinking, and novel therapeutics to solve these issues.
Felicity Pharma is disrupting the existing antidepressant markets.
The global antidepressant market is set to reach $21.28 billion by 2025. We want to shift towards a more beneficial solution for those in need.
We aim to elevate women’s health and autonomy, with
Felicity Pharma’s novel medicines, all rooted in evidence-based medicine.
By developing targeted female therapeutics, we address the unmet medical needs of women with hormone-related mood disorders, overlooked by modern medicine.
Cyclical changes in estrogen, progesterone and other hormones can disrupt the function of brain chemicals such as serotonin that control mood. While these changes are normal, some hormonal fluctuations increase the risk of developing severe and disabling forms of depression during a woman’s lifetime.
Women with mood disorders often have other symptoms including irritability, insomnia, anxiety and memory symptoms that are neglected. The current treatments including SSRIs are ineffective.
Women with mood disorders often have other symptoms including irritability, insomnia, anxiety and memory symptoms that are neglected.
Mood disorders in women are treated the same as men and do not take into account their biological differences.
FOUNDER, CHIEF EXECUTIVE OFFICER
Olivia is an American entrepreneur and cannabis business mogul. She founded one of the first ancillary cannabis companies, Cannabrand in 2013. Olivia is passionate about changing the paradigm of women’s health. Olivia is the intuitive leader of marketing and business revolution. Being the pioneer behind a movement to destigmatize cannabis, Olivia is a thought leader and visionary in every sense. She recognized the opportunity that the cannabis industries would offer long before it was widely accepted. This uniquely positioned her to disrupt the expectation that cannabis should remain a fringe industry. Olivia has been recognized on Forbes, PRWeek’s Top 50 Innovators, Adweek’s Young Influentials lists and is a contributor to Adweek and Rolling Stone.
FOUNDER, CHIEF SCIENCE OFFICER
Geraldine (Gigi), MD, conducted her residency at Mount Sinai, in NYC and specializes in chronic pain and traumatic brain injury (for over 25 years), and has consulted in psychedelic pharma and initial patent filing. Previously, she co-founded Monarch Labs, and was a managing director at Athena BioVentures. She has received the Sidney and Elizabeth Licht award for excellence in her writing. Gigi is leading the molecule vision for Felicity Pharma and is confident in tranformorming modern medicine.
Chief Operating Officer
Tom started his life science career at Immunex before taking on additional product management responsibilities at Pharmacia and QLT. Tom was Co-founder and CEO of Superna Life Sciences, a specialty pharmaceutical company, and served as CEO of ImmunoPrecise Antibodies where he led the company through its transition to becoming publicly traded. Tom was also most recently the COO of TRYP Therapeutics.
Tom earned a BSc in chemistry from Loyola University Chicago and an MBA from Vanderbilt University.
Scientific & Business Advisor
Scientific Advisor
Dr. Josh Woolley is an Associate Professor in Residence in the Department of Psychiatry and Behavioral Sciences at the University of California, San Francisco (UCSF) as well as a staff psychiatrist in Mental Health at the San Francisco Veterans Affairs Medical Center (SFVAMC). He is Board Certified in Psychiatry by the American Board of Psychiatry and Neurology. He is the Director of the Bonding and Attunement in Neuropsychiatric Disorders (BAND) lab at UCSF that focuses on understanding and treating social deficits in neuropsychiatric disorders including schizophrenia, substance use disorders, and mood disorders. He is also the Director of the Translational Psychedelic Research (TrPR) Program at UCSF, which brings together scientists and care providers across disciplines to understand how psilocybin, LSD, ketamine, MDMA, and related compounds impact the brain and other organ systems.
a part of my series about the women in wellness, I had the pleasure of interviewing Olivia Mannix. Olivia Mannix is an entrepreneur and cannabis &
Nikhita Singhal’s breath still catches when she talks about how her life changed. A psychiatry resident at the University of Toronto, Singhal says it was
Female Focused
Women want and deserve products that are created to be gender specific and Female’s want and deserve products that are created to be gender specific. Women are underserved in the current healthcare market.
